Effect of sodium valproate on aripiprazole pharmacokinetics and initial dosage optimization in bipolar disorder

Table 1 Demographic data of bipolar disorder patients receiving aripiprazole (n = 24)

Characteristic	mean ± SD	Median (range)
Gender (men/women)	15/9
Age (years)	36.55 ± 9.47	33.25 (18.05-66.50)
Weight (kg)	74.55 ± 12.03	75.00 (50.00-105.00)
Albumin (g/L)	43.06 ± 3.26	42.80 (36.10-49.80)
Globulin (g/L)	25.37 ± 3.04	24.80 (19.10-31.20)
Alanine transaminase (IU/L)	24.92 ± 14.41	21.00 (9.00-68.00)
Aspartate transaminase (IU/L)	18.78 ± 5.89	18.00 (11.00-41.00)
Creatinine (μmol/L)	64.33 ± 9.54	63.00 (44.00-88.00)
Urea (mmol/L)	3.93 ± 1.26	3.66 (2.12-7.50)
Total protein (g/L)	68.42 ± 4.66	68.90 (58.30-77.80)
Triglyceride (mmol/L)	2.25 ± 1.10	2.12 (0.71-6.65)
Direct bilirubin (μmol/L)	2.75 ± 1.30	2.50 (0.60-5.90)
Total bilirubin (μmol/L)	8.44 ± 3.40	8.30 (2.50-17.70)
Hematocrit (%)	41.57 ± 2.98	42.00 (34.50-46.90)
Hemoglobin (g/L)	137.63 ± 10.57	138.00 (115.00-155.00)
Mean corpuscular hemoglobin (pg)	31.05 ± 0.98	31.20 (29.10-33.70)
Mean corpuscular hemoglobin concentration (g/L)	330.96 ± 6.82	331.00 (314.00-344.00)